Research programme: SNA based therapeutics - Exicure
Alternative Names: SNA constructs - Exicure; SNA targeting IL17RA - Exicure; SNA targeting IL4RA - Exicure; SNA targeting SCN9A - Exicure; Spherical nucleic acid constructs - ExicureLatest Information Update: 28 Mar 2023
At a glance
- Originator AuraSense Therapeutics
- Developer Dermelix Biotherapeutics; Exicure
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Eye disorder therapies; Neuroprotectants; Nucleic acids; Skin disorder therapies
- Mechanism of Action CLN3 protein expression modulators; Gene modulators; HD protein inhibitors; Immunomodulators; Immunosuppressants; Interleukin 1 beta modulators; Interleukin 4 receptor modulators; Nav1.7 voltage-gated sodium channel modulators; Survival of motor neuron 2 protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Neuropathic pain
Highest Development Phases
- Suspended Angelman syndrome; CNS disorders; Crohn's disease; Neuropathic pain; Ulcerative colitis
- No development reported Eye disorders; Huntington's disease; Inflammatory bowel diseases; Netherton Syndrome; Respiration disorders; Spinal muscular atrophy
- Discontinued Amyotrophic lateral sclerosis; Atopic dermatitis; Brain cancer; Epidermolysis bullosa; Fibrosis; Friedreich's ataxia; Lymphoma; Neuronal ceroid lipofuscinosis; Transplant rejection